A Phase 1 interventional study of Recombinant human hyaluronidase PH20 (rHuPH20) and Insulin lispro in Healthy, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-14.
Sponsored by Halozyme Therapeutics · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 150 under way, 2 of them phase 3. Insulin Resistance · United States.
Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 765th largest by enrollment of the 936 interventional ones that give a count, is one of 69 that started in 2009, is one of 116 in phase 1, and was the 360th registered.
2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.
Browse Insulin Resistance studies →117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–100
HealthPartners Institute · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
University of Colorado, Denver · Sites in United States
Ages 14–19
St. Louis University · Sites in United States
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 162 · Phase 3 45 · Phase 4 99
First in 1976; this study’s year is marked. 69 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 37 across the 936 interventional studies, 48 across the 174 observational. Of the 871 that completed or were terminated, 311 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 1,118 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 8 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
52 of the studies in Insulin Resistance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03947697University of Texas, El PasoImproving Glycemic Control With Electrical Stimulation | 2026-11-25 |
| NCT05958368Pennington Biomedical Research CenterAssessing the Value of Avocados on Glycemic Control in Type 2 Diabetes | 2026-11-30 |
| NCT05441982Virginia Polytechnic Institute and State UniversitySaccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes | 2026-11-30 |
| NCT03318094Vanderbilt University Medical CenterRole of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity | 2026-11-30 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,118 studies in Insulin Resistance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, Phase 1, randomized, double-blind, 6-way crossover study to determine insulin pharmacokinetics, insulin glucodynamics, safety, and tolerability of subcutaneously administered dose(s) of insulin lispro + recombinant human hyaluronidase PH20 (rHuPH20), insulin lispro alone, insulin glulisine + rHuPH20, insulin glulisine alone, insulin aspart + rHuPH20, and insulin aspart alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout. Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart. Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart. Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart.
Drug: Recombinant human hyaluronidase PH20 (rHuPH20) · Drug: Insulin lispro · Drug: Insulin glulisine · Drug: Insulin aspart
Also known as: HYLENEX, PH20
Also known as: Humalog, Lispro
Also known as: Apidra, Glulisine
Also known as: NovoLog, Aspart
Area Under the Concentration-time Curve for Serum Insulin From Time 0 to 60 Minutes (AUC0-60)
Area under the concentration (AUC)-time curve was derived as the area under the serum insulin concentration profile from 0 to 60 minutes. Blood samples were taken 30, 20, and 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and at 20, 25, 30, 45, and 60 mins after each injection.
Time frame: Predose up to 60 minutes postdose
Time to Maximum Serum Insulin Concentration (Tmax)
Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: Predose up to 480 minutes postdose
Time to Early and Late 50% Maximum Serum Insulin Concentration (t[50%Max])
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: Predose up to 480 minutes postdose
Time to Maximum Glucose Infusion Rate (tGIR[Max])
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: Predose up to 480 minutes postdose
Percentage of Total Area Under the Concentration-time Curve for Serum Insulin Attained by Time t (AUC0-t)
Percentage of total area under the concentration (AUC)-time curve at 15, 30, 60, 120 minutes after injection was measured. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and at 90 and 120 mins after each injection.
Time frame: Predose up to 120 minutes postdose
Time to Percentage of Total Insulin Exposure
Time to 10% and 50% of total insulin exposure was measured. Samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: Predose up to 480 minutes postdose
| Milestone | Lispro+PH20, Lispro, Glulis, Glulis+PH20, Aspart, Aspart+PH20 | Glulis+PH20, Glulis, Lispro+PH20, Lispro, Aspart+PH20, Aspart | Lispro, Lispro+PH20, Aspart, Aspart+PH20, Glulis, Glulis+PH20 | Glulis, Glulis+PH20, Aspart+PH20, Aspart, Lispro+PH20, Lispro | Aspart+PH20, Aspart, Glulis+PH20, Glulis, Lispro, Lispro+PH20 | Aspart, Aspart+PH20, Lispro, Lispro+PH20, Glulis+PH20, Glulis |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 3 | 2 | 3 | 2 |
| Received at least 1 dose of study drug | 2 | 2 | 3 | 2 | 3 | 2 |
| Completed | 2 | 2 | 3 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+PH20, Lispro, Glulis, Glulis+PH20, Aspart, Aspart+PH20 | Glulis+PH20, Glulis, Lispro+PH20, Lispro, Aspart+PH20, Aspart | Lispro, Lispro+PH20, Aspart, Aspart+PH20, Glulis, Glulis+PH20 | Glulis, Glulis+PH20, Aspart+PH20, Aspart, Lispro+PH20, Lispro | Aspart+PH20, Aspart, Glulis+PH20, Glulis, Lispro, Lispro+PH20 | Aspart, Aspart+PH20, Lispro, Lispro+PH20, Glulis+PH20, Glulis |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 3 | 2 | 3 | 2 |
| Completed | 2 | 2 | 3 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+PH20, Lispro, Glulis, Glulis+PH20, Aspart, Aspart+PH20 | Glulis+PH20, Glulis, Lispro+PH20, Lispro, Aspart+PH20, Aspart | Lispro, Lispro+PH20, Aspart, Aspart+PH20, Glulis, Glulis+PH20 | Glulis, Glulis+PH20, Aspart+PH20, Aspart, Lispro+PH20, Lispro | Aspart+PH20, Aspart, Glulis+PH20, Glulis, Lispro, Lispro+PH20 | Aspart, Aspart+PH20, Lispro, Lispro+PH20, Glulis+PH20, Glulis |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 3 | 2 | 3 | 2 |
| Completed | 2 | 2 | 3 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+PH20, Lispro, Glulis, Glulis+PH20, Aspart, Aspart+PH20 | Glulis+PH20, Glulis, Lispro+PH20, Lispro, Aspart+PH20, Aspart | Lispro, Lispro+PH20, Aspart, Aspart+PH20, Glulis, Glulis+PH20 | Glulis, Glulis+PH20, Aspart+PH20, Aspart, Lispro+PH20, Lispro | Aspart+PH20, Aspart, Glulis+PH20, Glulis, Lispro, Lispro+PH20 | Aspart, Aspart+PH20, Lispro, Lispro+PH20, Glulis+PH20, Glulis |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 3 | 2 | 3 | 2 |
| Completed | 2 | 2 | 3 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+PH20, Lispro, Glulis, Glulis+PH20, Aspart, Aspart+PH20 | Glulis+PH20, Glulis, Lispro+PH20, Lispro, Aspart+PH20, Aspart | Lispro, Lispro+PH20, Aspart, Aspart+PH20, Glulis, Glulis+PH20 | Glulis, Glulis+PH20, Aspart+PH20, Aspart, Lispro+PH20, Lispro | Aspart+PH20, Aspart, Glulis+PH20, Glulis, Lispro, Lispro+PH20 | Aspart, Aspart+PH20, Lispro, Lispro+PH20, Glulis+PH20, Glulis |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 3 | 2 | 3 | 2 |
| Completed | 2 | 2 | 3 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration (AUC)-time curve was derived as the area under the serum insulin concentration profile from 0 to 60 minutes. Blood samples were taken 30, 20, and 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and at 20, 25, 30, 45, and 60 mins after each injection.
| minutes*nanomolars (min*nM) | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve for Serum Insulin From Time 0 to 60 Minutes (AUC0-60) | 11667.14 ± 4085.00 | 23807.14 ± 6657.73 | 10687.14 ± 5532.49 | 27850.00 ± 9684.94 | 8065.00 ± 3138.37 | 20778.57 ± 6383.05 |
Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| minutes | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| Time to Maximum Serum Insulin Concentration (Tmax) | 80.36 ± 25.38 | 41.43 ± 12.47 | 67.50 ± 32.09 | 41.07 ± 17.56 | 85.71 ± 35.99 | 43.57 ± 12.92 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| minutes | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| early t(50%max) | 21.06 ± 9.60 | 10.16 ± 4.90 | 30.69 ± 12.58 | 18.96 ± 5.27 | 31.93 ± 8.15 | 17.98 ± 5.22 |
| late t(50%max) | 195.43 ± 48.63 | 118.92 ± 33.57 | 176.79 ± 30.00 | 89.59 ± 21.38 | 193.50 ± 45.94 | 102.82 ± 24.74 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| minutes | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| Time to Maximum Glucose Infusion Rate (tGIR[Max]) | 141.93 ± 71.18 | 113.36 ± 69.85 | 160.14 ± 71.36 | 103.57 ± 58.83 | 158.79 ± 52.34 | 96.93 ± 56.65 |
Percentage of total area under the concentration (AUC)-time curve at 15, 30, 60, 120 minutes after injection was measured. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and at 90 and 120 mins after each injection.
| percentage of total AUC | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| AUC0-15 | 2.02 ± 1.10 | 5.29 ± 2.06 | 0.68 ± 0.65 | 2.38 ± 1.24 | 0.56 ± 0.30 | 2.92 ± 2.28 |
| AUC0-30 | 7.09 ± 3.40 | 15.82 ± 5.56 | 3.88 ± 2.71 | 13.81 ± 5.37 | 3.54 ± 1.90 | 13.66 ± 7.05 |
| AUC0-60 | 20.68 ± 8.07 | 39.45 ± 10.64 | 18.72 ± 7.74 | 42.88 ± 8.89 | 16.85 ± 6.54 | 41.51 ± 12.06 |
| AUC0-120 | 50.35 ± 12.69 | 71.70 ± 11.07 | 50.14 ± 12.10 | 77.00 ± 7.54 | 47.97 ± 12.32 | 77.37 ± 8.80 |
Time to 10% and 50% of total insulin exposure was measured. Samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| minutes | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| Time to 10% of total insulin exposure | 39.59 ± 9.95 | 23.39 ± 6.38 | 46.56 ± 11.89 | 26.35 ± 5.60 | 48.42 ± 9.96 | 26.99 ± 6.57 |
| Time to 50% of total insulin exposure | 123.65 ± 27.48 | 78.64 ± 18.82 | 123.39 ± 27.87 | 70.97 ± 12.61 | 130.86 ± 30.04 | 72.53 ± 14.86 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glulisine Alone | — | 0/14 (0%) | 1/14 (7.1%) |
| Glulisine + rHuPH20 | — | 0/14 (0%) | 2/14 (14.3%) |
| Lispro Alone | — | 0/14 (0%) | 2/14 (14.3%) |
| Lispro + rHuPH20 | — | 0/14 (0%) | 3/14 (21.4%) |
| Aspart Alone | — | 0/14 (0%) | 2/14 (14.3%) |
| Aspart + rHuPH20 | — | 0/14 (0%) | 2/14 (14.3%) |
| Event | Glulisine Alone | Glulisine + rHuPH20 | Lispro Alone | Lispro + rHuPH20 | Aspart Alone | Aspart + rHuPH20 |
|---|---|---|---|---|---|---|
| Infusion site anaesthesiaGeneral disorders | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 |
| Infusion site painGeneral disorders | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 | 1/14 |
| Infusion site abscessInfections and infestations | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 |
| RhinitisInfections and infestations | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 |
| ContusionInjury, poisoning and procedural complications | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 |
| HeadacheNervous system disorders | 1/14 | 1/14 | 1/14 | 1/14 | 1/14 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 |
All randomized participants.
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 33.7 ± 8.96 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 6 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 2 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Study |
|---|---|
| United States | 14 |
The record gives a start of Sep 2009, a primary completion of Feb 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)